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Background: Malaria remains a major public health problem in Togo. The national malaria control programme in
Togo changed the anti-malarial treatment policy from monotherapy to artemisinin combination therapy in 2004.
This study reports the results of therapeutic efficacy studies conducted on artemether-lumefantrine and
artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Togo, between 2005
and 2009.
Methods: Children between 6 and 59 months of age, who were symptomatically infected with P. falciparum, were
treated with either artemether-lumefantrine or artesunate-amodiaquine. The primary end-point was the 28-day cure
rate, PCR-corrected for reinfection and recrudescence. Studies were conducted according to the standardized WHO
protocol for the assessment of the efficacy of anti-malarial treatment. Differences between categorical data were
compared using the chi-square test or the Fisher’s exact test where cell counts were ≤ 5. Differences in continuous
data were compared using a t-test.
Results: A total of 16 studies were conducted in five sentinel sites, with 459, 505 and 332 children included in
2005, 2007 and 2009, respectively. The PCR-corrected 28-day cure rates using the per-protocol analysis were
between 96%-100% for artemether-lumefantrine and 94%-100% for artesunate-amodiaquine.
Conclusions: Both formulations of artemisinin-based combination therapy were effective over time and no severe
adverse events related to the treatment were reported during the studies.
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Malaria remains a major public health problem in Togo,
an area of high transmission, with prevalence highest
during the rainy season. Children carry the highest bur-
den: in 2009, 56% of all reported cases and 73% of all
reported deaths occurred among children under five
years of age [1]. In 2001, following an increase in Plas-
modium falciparum resistance to anti-malarial medi-
cines, the Togo National Malaria Control Programme
(NMCP) set up a routine surveillance system, with five
sentinel sites covering the distinct epidemiological zones
of the country. Between 2001 and 2003, treatment fail-
ures with chloroquine and sulphadoxine−pyrimethamine
reached 63% and 26%, respectively [2]. A national con-
sensus meeting in May 2004 led to the adoption of two
different forms of artemisinin-based combination ther-
apy (ACT) for the treatment of uncomplicated malaria
in Togo: artemether-lumefantrine and artesunate-amo-
diaquine. The NMCP began to monitor the therapeutic
efficacy of these two combinations in 2005. This article
reports the efficacy of both forms of ACT for the treat-
ment of uncomplicated malaria between 2005 and 2009.
Methods
Sentinel sites
The studies were conducted in the following sites: 1)
Agbalpédogan Jérusalem Medical Centre and Adakpamé
District Hospital in the capital city of Lomé; 2) La Provi-
dence Medical Centre in Kouvé; 3) Sodoké and Kpanga-
lam “Bon Secours” Medical Centres located in Sodoké;
4) Doufelgou District Hospital in Niamtougou; and 5)
Tantigou “Yendoubé” Paediatric Hospital in Dapaong.
The last four sentinel sites extend north from Lomé, in
the order listed above, by 92 km, 350 km, 425 km and
620 km, respectively. Studies were conducted during the
high transmission season for malaria, between October
and December, except for Lomé, where the study was
conducted from August to November.
Study design
The studies were based on the standardized World
Health Organization (WHO) protocol for the assessment
of the efficacy of anti-malarial treatment [3]. Patients
who presented for care at one of the health centres were
eligible for inclusion if they met the following criteria:
age between 6 and 59 months; fever (≥ 37.5 °C); P. fal-
ciparum mono-infection with parasite density between
2,000 and 200,000 asexual parasites/mm3. Exclusion cri-
teria included: one or more signs of severe or compli-
cated malaria, mixed infection or infection with another
species, malnutrition, concomitant disease, chronic or
severe diseases, hypersensitivity or contra-indication to
the study drugs and absence of informed consent of the
parents. Clinical examination, including measurement ofaxillary temperature and blood smear for parasite
counts, was performed at enrolment and on day 1, 2, 3,
7, 14, 21 and 28. Parasite counts were determined on
Giemsa-stained thick films and recorded as the number
of parasites per 200 white blood cells at admission and
per 1,000 white cells on follow-up days based on a puta-
tive count of 6,000 white blood cells per microlitre of
blood. The presence of gametocytes was also recorded
in the 2007 and 2009 trials. Changes to haemoglobin
levels after ACT treatment in 2007 and 2009 were mea-
sured using Hemocue haemoglobinometer. Capillary
blood was sampled for haemoglobin at day 0, day 14 and
day 28. All studies were approved by the Bioethics com-
mittee of the Ministry of Health and WHO Ethical Re-
search Committee in 2007. Sample size was calculated
according to WHO recommendations [4]. The sample
size was estimated with a treatment success of 95%, the
minimum expected efficacy of an ACT in a region where
it has never been used. The confidence level was esti-
mated at 95% and a precision level of 10%, for a target
sample size of 50 children per treatment arm and per
site. An additional 20% was added to ensure the sample
size would be achieved after patients were excluded due
to loss to follow-up and withdrawals.
Study medicines
Artemether-lumefantrine (Novartis Pharma, Switzerland)
tablets containing 20 mg of artemether and 120 mg lume-
fantrine were administered every 12 hours over 3 days.
Treatment was given without co-administration of fatty
food. Weight-based dosing was applied, with one tablet
for children weighing 5-14 kg and two tablets for children
weighing 15-24 kg. Artesunate and amodiaquine were
administered at an average dose of 4 mg/kg/day and
10 mg/kg/day over 3 days, respectively. Two different pre-
sentations of artesunate-amodiaquine were used: in 2005
and 2007, artesunate was purchased from Sanofi Synthé-
labo (France), and amodiaquine was supplied by Hoechst
Marion Roussel (France). A co-blister of artesunate-
amodiaquine manufactured by sanofi aventis (France) was
used in 2009. The medicines were administered under
supervision and allocated randomly. The purpose of the
studies was not to compare the efficacy of the two combi-
nations, but to monitor their efficacy independently.
Outcome assessment
Treatment outcomes were classified based on an assess-
ment of parasitological and clinical outcomes, according
to the methods recommended by WHO in 2003 [3],
with modifications suggested by WHO in 2005 [5]. Un-
like the 2003 protocol, which limits late treatment fail-
ures to patients with parasites on day 28, the 2005
modification considers a patient to have failed treatment
when parasites are detected on any day between day 7
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classified on day 28 as either: early treatment failure
(ETF), late clinical failure (LCF), late parasitological fail-
ure (LPF), or adequate clinical and parasitological re-
sponse (ACPR). All treatment failures (TF = ETF + LCF
+ LPF) were treated with quinine at the day of failure.
Children who developed severe malaria during the
follow-up were treated with parenteral quinine. The pro-
portion of cases still positive on day 3 was also recorded.
PCR was conducted in order to distinguish between re-
crudescence and reinfection. In 2005, only two molecu-
lar markers for PCR (msp1 and msp2) were used. In
2007 and 2009, all three molecular markers (msp1, msp2
and glurp) were used. Parasite DNA was extracted from
blood spots collected on day 0 and on the day of re-
appearance of asexual parasitaemia [6]. Patients who
were lost to follow-up, had protocol violations, whose
treatment failure was due to reinfection, or whose type
of treatment failure could not be determined through
PCR were excluded from the per-protocol analysis, as
recommended in the WHO protocol [3].
Statistical analysis
All data were entered twice in the WHO MicrosoftW
Office Excel spreadsheet. Analysis was conducted with
Stata/IC 11.0 (Stata Corporation, College Station, Texas
77845 USA). Differences between categorical data were
compared using the chi-square test or the Fisher’s exact
test where cell counts were ≤ 5. Differences in continu-
ous data were compared using a t-test. Exact 95%Table 1 Patient characteristics at the time of admission for tr
(AL) and artesunate-amodiaquine (ASAQ), by sentinel site an
drug site district province year n male/female me
yea
AL Dapaong Tone Savanes 2005 75 38/37 3.4
AL Dapaong Tone Savanes 2009 82 45/37 3.0
AL Kouvé Yoto Maritime 2005 78 43/35 2.6
AL Kouvé Yoto Maritime 2009 84 50/34 2.6
AL Lomé Lomé Maritime 2007 86 51/35 3.1
AL Niamtougou Doufelgou Kara 2005 76 42/34 3.4
AL Niamtougou Doufelgou Kara 2007 82 47/35 2.8
AL Sokodé Tchaoudjo Centrale 2007 82 48/34 2.9
ASAQ Dapaong Tone Savanes 2005 75 34/41 3.2
ASAQ Dapaong Tone Savanes 2009 81 42/39 3.1
ASAQ Kouvé Yoto Maritime 2005 78 48/30 2.3
ASAQ Kouvé Yoto Maritime 2009 85 39/46 2.3
ASAQ Lomé Lomé Maritime 2007 85 47/38 2.9
ASAQ Niamtougou Doufelgou Kara 2005 77 37/40 2.8
ASAQ Niamtougou Doufelgou Kara 2007 83 51/32 2.9
ASAQ Sokodé Tchaoudjo Centrale 2007 87 49/38 3.1confidence intervals were calculated for the treatment
failure rates.
Results
Patients treated with artesunate-amodiaquine (n = 651)
had a sex ratio of 1.1, a mean age of 2.7 years (standard
deviation (SD) = 1.3 years), a mean weight of 12.2 kg
(SD= 3.1 kg), and a mean temperature of 38.7 °C
(SD=1.0 °C). The geometric mean parasitaemia on day 0
was 23,494/μl (95% CI: 21,376-25,822). Patients treated
with artemether-lumefantrine (n= 645) had a sex ratio of
1.3, a mean age of 2.9 years (SD=1.3 years), a mean
weight of 12.5 kg (SD= 3.1 kg), a mean temperature of
38.7 °C (SD=1.0 °C). The geometric mean parasitaemia
on day 0 was 21,183/μl (95% CI: 19,336-23,206).
Differences in patient characteristics on admission
were investigated among studies conducted at the same
site and on the same treatment between 2005 and 2007
(Niamtougou), and 2005 and 2009 (Dapaong and Kouvé)
(Table 1). Studies in Lomé and Sokodé were conducted
in 2007 only. In the Kouvé studies of artesunate-amodia-
quine, there was a higher proportion of males in 2005
(61%) than in 2009 (46%) (P = 0.04). In Niamtougou, the
mean weight of patients was higher in 2005 (13.8 kg)
than in 2007 (11.9 kg) (P < 0.001). No other differences
were observed in admission characteristics over time.
The overall PCR-corrected treatment failure rates
remained low: between 0-4.4% for artemether-lumefan-
trine, and 0-6% for artesunate-amodiaquine (Table 2).
Both treatments resulted in a rapid clearance of theeatment of P. falciparum with artemether-lumefantrine









(1.5) 13.3 (3.5) 38.8 (0.8) 22037 (17390-27925)
(1.3) 12.2 (3.1) 38.5 (0.6) 34509 (26784-44464)
(1.3) 11.7 (3.2) 38.6 (1.0) 16866 (13011-21863)
(1.2) 11.7 (2.9) 38.8 (0.9) 22043 (16877-28791)
(1.4) 13.1 (3.1) 39.2 (0.9) 24058 (18724-30911)
(1.3) 13.8 (3.1) 38.4 (0.8) 13074 (9822-17403)
(1.2) 11.9 (2.7) 38.6 (1.0) 19430 (15209-24823)
(1.3) 12.3 (2.9) 38.4 (0.8) 21677 (16947-27727)
(1.4) 12.7 (3.1) 38.5 (0.8) 27339 (21628-34559)
(1.4) 12.6 (3.0) 38.6 (0.8) 36599 (28729-46624)
(1.3) 11.2 (3.0) 38.7 (1.1) 16004 (11861-21596)
(1.1) 11.1 (2.8) 38.9 (1.0) 21346 (16300-27954)
(1.3) 12.5 (2.9) 39.0 (1.0) 26065 (19569-34717)
(1.5) 12.6 (3.9) 38.3 (0.9) 15893 (11593-21789)
(1.2) 11.9 (2.8) 38.6 (1.0) 18118 (14330-22906)
(1.2) 13.1 (3.1) 38.7 (0.9) 35226 (28287-43865)
Table 2 Parasitological and clinical outcomes among patients treated for P. falciparum malaria with artemether-lumefantrine (AL) and artesunate-amodiaquine
(ASAQ), by year and site (2005-2009)
Non-PCR-corrected PCR-corrected
Drug Site Year n excl/loss ACPR LCF LPF TF (%) (Exact 95% CI) excl/loss ACPR LCF LPF TF (%) (Exact 95% CI) Kaplan-Meier
AL Dapaong 2005 75 1 71 3 0 3 (4.1) (0.8-11.4) 4 71 0 0 0 (0.0) (0.0-5.1) 0.0 (0.0-0.0)
AL Dapaong 2009 82 0 73 2 7 9 (11.0) (5.1-19.8) 9 73 0 0 0 (0.0) (0.0-4.9) 0.0 (0.0-0.0)
AL Kouvé 2005 78 3 65 4 6 10 (13.3) (6.6-23.2) 10 65 0 3 3 (4.4) (0.9-12.4) 4.1 (1.3-12.2)
AL Kouvé 2009 84 0 68 2 14 16 (19.1) (11.3-29.1) 16 68 0 0 0 (0.0) (0.0-5.3) 0.0 (0.0-0.0)
AL Lomé 2007 86 7 72 4 3 7 (8.9) (3.6-17.4) 13 72 1 0 1 (1.4) (0.0-7.4) 1.3 (0.2-8.8)
AL Niamtougou 2005 76 0 67 1 8 9 (11.8) (5.6-21.3) 7 67 1 1 2 (2.9) (0.4-10.1) 2.7 (0.7-10.5)
AL Niamtougou 2007 82 1 56 10 15 25 (30.9) (21.1-42.1) 26 56 0 0 0 (0.0) (0.0-6.4) 0.0 (0.0-0.0)
AL Sokodé 2007 82 6 66 2 8 10 (13.2) (6.5-22.9) 15 66 0 1 1 (1.5) (0.0-8.0) 1.4 (0.2-9.7)
AL Overall 645 18 538 28 61 89 (14.2) (11.6-17.2) 100 538 2 5 7 (1.3) (0.3-4.1) 1.2 (0.5-26.2)
ASAQ Dapaong 2005 75 0 74 0 1 1 (1.3) (0.0-7.2) 1 74 0 0 0 (0.0) (0.0-4.9) 0.0 (0.0-0.0)
ASAQ Dapaong 2009 81 0 74 1 6 7 (8.6) (3.5-17.0) 6 74 1 0 1 (1.3) (0.0-7.2) 1.3 (0.2-8.8)
ASAQ Kouvé 2005 78 3 72 0 3 3 (4.0) (0.8-11.4) 6 72 0 0 0 (0.0) (0.0-5.1) 0.0 (0.0-0.0)
ASAQ Kouvé 2009 85 1 78 2 4 6 (7.1) (2.7-14.9) 7 78 0 0 0 (0.0) (0.0-4.6) 0.0 (0.0-0.0)
ASAQ Lomé 2007 85 3 79 1 2 3 (3.7) (0.8-10.3) 6 79 0 0 0 (0.0) (0.0-4.6) 0.0 (0.0-0.0)
ASAQ Niamtougou 2005 77 2 63 1 11 12 (16.0) (8.6-26.3) 10 63 0 4 4 (6.0) (1.7-14.6) 5.6 (2.1-14.2)
ASAQ Niamtougou 2007 83 6 66 3 8 11 (14.3) (7.4-24.1) 16 66 0 1 1 (1.5) (0.0-8.0) 1.3 (0.2-9.1)
ASAQ Sokodé 2007 87 4 74 1 8 9 (10.8) (5.1-19.6) 13 74 0 0 0 (0.0) (0.0-4.9) 0.0 (0.0-0.0)
ASAQ Overall 651 19 580 9 43 52 (8.2) (6.2-10.6) 65 580 1 5 6 (1.0) (0.3-3.5) 1.0 (0.3-2.2)

















Table 3 Mean (standard deviation) hemoglobin levels at
day 0, day 14 and day 28, following treatment with
artemether-lumefantrine (AL), artesunate-amodiaquine
(ASAQ), in 2007 and 2009
2007 2009
D0 D14 D28 D0 D14 D28
AL 9.8 (1.8) 10.2 (1.5) 10.9 (1.5) 9.2 (1.6) 9.8 (1.3) 10.5 (1.3)
ASAQ 9.3 (1.8) 10.1 (1.5) 11.0 (1.4) 9.2 (1.7) 9.8 (1.3) 10.9 (1.3)
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patients included in the 16 studies, 93% cleared their
parasitaemia by day 2 and 98.4% by day 3. Patients still
positive on day 2 or day 3 presented with very low para-
sitaemia, usually less than 50 parasites/μl. The propor-
tion of patients positive on day 3 was 2.2% in 2005, 1.6%
in 2007, and 0.6% in 2009.
Non-PCR-corrected treatment failure rates among
studies conducted in 2005, 2007 and 2009 were 8.4%,
13.6% and 11.5%, respectively. However, the proportion
of non-PCR-corrected treatment failures subsequently
PCR-corrected as recrudescence decreased from 23.7%
in 2005, to 4.6% in 2007 and 2.6% in 2009. There was a
corresponding increase in the proportion classified as
reinfections by PCR, from 55.3% in 2005, to 80% in 2007
and 84.2% in 2009 (P = 0.004). This increase was
observed in all three sites where studies were conducted
twice within the four-year period, but the increase was
most pronounced in Kouvé, with 28.6% in 2005 and
71.4% in 2009 (P = 0.04), and in Niamtougou, where the
proportion of non-PCR-corrected treatment failures sub-
sequently PCR-corrected as reinfections increased from
24.4% in 2005 to 75.6% in 2007 (P = 0.001). The increase
was consistent in both treatment groups. No severe ad-
verse events related to the ACT were reported during
the 16 studies.Table 4 Patients with gametocytes on admission and followin
artesunate-amodiaquine (ASAQ), by site and year (2007 to 20
Drug Site District Province Year
AL Dapaong Tone Savanes 2009
AL Kouvé Yoto Maritime 2009
AL Lomé Lomé Maritime 2007
AL Niamtougou Doufelgou Maritime 2007
AL Sokodé Tchaoudjo Centrale 2007
ASAQ Dapaong Tone Savanes 2009
ASAQ Kouvé Yoto Maritime 2009
ASAQ Lomé Lomé Maritime 2007
ASAQ Niamtougou Doufelgou Maritime 2007
ASAQ Sokodé Tchaoudjo Centrale 2007Haemoglobin levels for subjects in both treatment
groups increased progressively from day 0 to day 14 and
to day 28 (Table 3). Significant differences in haemoglo-
bin levels were observed on day 14 and day 28 when
compared to day 0 for all sites and treatments (P < 0.05),
except the artemether-lumefantrine studies conducted in
Lomé and Niamtougou in 2007 and both forms of ACT
in Dapong in 2009, where the mean increase was less
than 0.3 g/dl.
While there was some variation in the proportion of
patients with gametocytes on day 0, no differences were
found among sites or treatment regimens at other time
points (Table 4). There was a rapid reduction in gameto-
cytes, and no new gametocytes appeared over the 28-day
period. No data on gametocytes were available from the
studies conducted in 2005.
Discussion
These studies showed the high therapeutic efficacy of
artemether-lumefantrine and artesunate-amodiaquine in
Togo between 2005 and 2009. The studies also demon-
strated the significant improvement of haemoglobin
levels following treatment. In addition, the artemisinin’s
gametocytocidal effect was observed by the initial, rapid
reduction in gametocytes, and the failure of any new
gametocytes to appear over the 28-day period.
In Togo, the efficacy of artemether-lumefantrine was
high and did not change between 2005 and 2009, despite
the absence of co-administration of fat. This is consist-
ent with a review of studies from sub-Saharan Africa,
where it was found that the fat content of standard
meals or breast milk was adequate for absorption of
lumefantrine [7]. In 2009, artemether-lumefantrine was
the first-line treatment in 29 African countries [8]. In a
review of 140 studies of the therapeutic efficacy of
artemether-lumefantrine in Africa [8], a PCR-corrected
treatment failure rate of higher than 10% was observedg treatment with artemether-lumefantrine (AL)
09)
Gametocytes
day 0 day 7 day 14 day 21 day 28
0/82 0/82 0/82 0/80 0/76
8/84 3/84 1/84 1/84 1/83
0/85 1/81 0/79 0/79 0/76
9/82 3/81 1/81 0/79 0/71
2/82 0/76 0/76 0/76 0/73
0/81 0/81 0/81 0/79 0/76
7/85 2/85 0/85 0/84 0/84
6/84 3/82 0/82 1/82 0/82
11/83 7/78 7/79 2/77 0/76
5/87 5/83 6/83 2/82 1/81
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kina Faso [9].
Similarly, the efficacy of artesunate-amodiaquine was
high in Togo, and did not change between 2005 and
2009. Two different presentations were used in these
studies: loose tablets were used in 2005 and 2007, and
co-blistered treatment was used in 2009. Despite differ-
ent presentations, the treatment outcome did not vary
significantly over time. In 2009, artesunate-amodiaquine
was the first-line treatment for uncomplicated malaria in
22 African countries [8]. However, the 28-day thera-
peutic efficacy of artesunate-amodiaquine varies sub-
stantially across the African continent [8,10] due to the
pre-existing resistance of amodiaquine, which also varies
across the continent [5]. In a 2003 study in Togo, amo-
diaquine was observed to be over 90% effective, although
follow-up was only 14 days [2].
The studies presented here showed an increase in the
proportion of reinfections detected in 2007 and 2009
when compared to 2005. The increase in the proportion
of reinfections was likely caused by the addition of a
third molecular marker, glurp, which improved the abil-
ity to distinguish between reinfection and recrudescence.
In 2005, only msp1 and msp 2 were used. When glurp
was added in 2007 and 2009, the molecular marker
detected 53% and 65% of the reinfections, respectively,
demonstrating its high ability to discriminate between a
reinfection and a recrudescence. Failure to use all three
molecular markers in PCR analyses may result in incor-
rect conclusions regarding the true efficacy of the ACT.
These findings demonstrate the importance of following
a standardized protocol to enable the comparison of
therapeutic efficacy results across sites and over time.
There are very few studies on therapeutic efficacy and
drug resistance in Togo. In a literature review, only one
publication on the therapeutic efficacy of ACT in Togo
was found [11]. Among 80 patients, 22 were seen on day
3, of whom 20 had cleared their parasites. However,
the conclusions from the 2007 study of artemether-
lumefantrine are limited, since treatment was not super-
vised and there was limited follow-up; parents were
instructed to return only if their child’s condition per-
sisted after 72 hours. Further, therapeutic efficacy is nor-
mally targeted among children under five years of age,




are both first-line medicines for the treatment of uncom-
plicated malaria in Togo, and both have shown high effi-
cacy. WHO only recommends a change in treatment
policy if the PCR-corrected treatment failure is higher
than 10%, which is not the case in Togo. Nevertheless,routine monitoring with adherence to standardized pro-
tocols should be continued in order to detect artemisi-
nin resistance if it emerges, and to monitor changes to
the therapeutic effect of the partner drug in an ACT.
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